SCHEMBL3487572

SCHEMBL3487572

CCc1cccc(Oc2ccc(N)c(N(C)C(=O)O)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.42
CTSD P07339 1/20 0.41
BACE1 P56817 1/20 0.41
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
FFAR1 O14842 5/20 0.38
TSHR P16473 2/20 0.38
ACHE P22303 2/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.38
CETP P11597 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
FDFT1 P37268 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487574 0.88 SMN1; SMN2 (0.40) TSHRACHEHSD17B10SMN1; SMN2KDM4E
SCHEMBL3487215 0.83 HSD17B1 (0.52) FFAR1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL3487615 0.83 SMN1; SMN2 (0.51) FFAR1HSD17B10SMN1; SMN2POLBFFAR4
SCHEMBL3487600 0.82 KDM4E (0.44) FFAR1L3MBTL1KDM4E
SCHEMBL3488475 0.81 MAPK14 (0.41) THRATHRBCETP
SCHEMBL3488318 0.81 ALOX5 (0.42) PTGESFFAR1L3MBTL1KDM4EALDH1A1
SCHEMBL3487537 0.79 KDM4E (0.45) THRATHRBL3MBTL1KDM4EALDH1A1
SCHEMBL3488177 0.79 HSD17B1 (0.44) FFAR1TDP1SMN1; SMN2POLBFFAR4
SCHEMBL3488383 0.79 PARP10 (0.45) SMN1; SMN2
SCHEMBL6543782 0.79 PARP10 (0.42) THRATHRBL3MBTL1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA PTGES 2180/4885CTSD 3852/4885BACE1 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.